The recommendation is specifically for patients who are intolerant of, or whose condition has had an inadequate response, or loss of response to previous biologic therapy or conventional therapy.
The decision from NICE was supported by data from True North, a pivotal phase 3 trial evaluating Zeposia as an induction and maintenance therapy versus placebo in adult patients with moderate-to-severe UC.
The trial demonstrated statistically significant and clinically meaningful results for clinical remission with Zeposia compared to placebo at induction at week one. Moreover, in the maintenance phase of the study at week 52, Zeposia demonstrated statistical significance in clinical remission versus placebo…
